Terms: = Bone cancer AND FAM46C, Q5VWP2, FLJ20202, ENSG00000183508, 54855 AND Treatment
3 results:
1. Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses.
Flietner E; Yu M; Poudel G; Veltri AJ; Zhou Y; Rajagopalan A; Feng Y; Lasho T; Wen Z; Sun Y; Patnaik MM; Callander NS; Asimakopoulos F; Wang D; Zhang J
Oncogene; 2023 May; 42(21):1751-1762. PubMed ID: 37031341
[TBL] [Abstract] [Full Text] [Related]
2. The clonal evolution during long-term clinical course of multiple myeloma.
Mishima Y; Mishima Y; Shirouchi Y; Nishimura N; Yokoyama M; Okabe T; Inoue N; Uryu H; Fukuta T; Hatake K; Terui Y
Int J Hematol; 2021 Feb; 113(2):279-284. PubMed ID: 32864713
[TBL] [Abstract] [Full Text] [Related]
3. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
[TBL] [Abstract] [Full Text] [Related]
